Previous 10 | Next 10 |
2024-05-09 07:30:10 ET More on X4 Pharmaceuticals X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside X4 Pharmaceuticals: PDUFA Excitement Ahead X4 Pharmaceuticals GAAP EPS of -$0.26...
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”),...
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor) XOLREMDI, the first drug indicated in patients with WHIM syndrome, received U.S. FDA approval in April 2024 BOSTON, May 09, 2024...
2024-05-09 00:59:38 ET Summary Barings BDC is a high-quality business development company trading at a discount to NAV of -14.6%, making it an attractive opportunity. BBDC's dividend yield is currently at 10.8% and is fully covered by the net investment income. BBDC's portfoli...
2024-05-08 13:09:38 ET Summary Ares Capital recently reported Q1 results. We look at the results and analyze their ramifications for both Ares Capital and the broader business development company sector. We also share our updated outlook for Ares Capital stock. ... ...
2024-05-07 04:34:00 ET Investors eager to bulk up their passive income streams can do so without breaking the bank. At recent prices, Hercules Capital (NYSE: HTGC) , Altria Group (NYSE: MO) , and AT&T (NYSE: T) offer an average yield of 8.5% at recent prices....
2024-05-06 23:50:49 ET Summary Hercules Capital reported robust quarterly earnings with record total gross fundings and a strong credit profile. The company's loan origination activity exceeded $600 million, indicating potential for special dividends. Despite being richly valu...
2024-05-04 07:35:34 ET Summary Hercules Capital, Inc. is a favorable investment choice in the VC-focused BDC sub-sector due to its strict underwriting standards and low debt levels. HTGC's Q1 2024 earnings report showed strong improvement across key metrics, with no contraction in...
2024-05-03 08:15:03 ET JMP Securities analyst issues OUTPERFORM recommendation for HTGC on May 3, 2024 06:48AM ET. The previous analyst recommendation was Outperform. HTGC was trading at $19.3 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-02 18:54:10 ET Hercules Capital, Inc. (HTGC) Q1 2024 Earnings Conference Call May 02, 2024 05:00 PM ET Company Participants Michael Hara - Director of IR Scott Bluestein - CEO & CIO Seth Meyer - CFO Conference Call Participants Crispin Lov...
News, Short Squeeze, Breakout and More Instantly...
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity ...
2024-07-10 08:00:08 ET Crispin Love from Piper Sandler issued a price target of $22.00 for HTGC on 2024-07-10 07:12:00. The adjusted price target was set to $22.00. At the time of the announcement, HTGC was trading at $20.5. The overall price target consensus is at $19.5...
2024-07-02 05:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...